

# Tanya Siddiqi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/140058/publications.pdf>

Version: 2024-02-01

136  
papers

12,651  
citations

94381

37  
h-index

25770

108  
g-index

136  
all docs

136  
docs citations

136  
times ranked

10938  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL. <i>Blood</i> , 2022, 139, 1794-1806.	0.6	66
2	Venetoclax in Previously Treated Waldenström Macroglobulinemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 63-71.	0.8	53
3	Management of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in the Era of Targeted Therapies. <i>Current Hematologic Malignancy Reports</i> , 2022, 17, 39-45.	1.2	0
4	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. <i>Blood</i> , 2022, 139, 3278-3289.	0.6	83
5	Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1580-1588.	0.6	0
6	Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 581.e1-581.e8.	0.6	61
7	Phase 1/2 study of zilovetamab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7520-7520.	0.8	2
8	ASPEN: Long-term follow-up results of a phase 3 randomized trial of zanubrutinib (ZANU) versus ibrutinib (IBR) in patients with Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2022, 40, 7521-7521.	0.8	14
9	Fixed-duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (tx) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Three-year follow-up from the FD cohort of the phase 2 CAPTIVATE study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7519-7519.	0.8	4
10	Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma. <i>Blood</i> , 2022, 140, 2697-2708.	0.6	15
11	NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 3.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 622-634.	2.3	33
12	Real-world outcomes of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) by race and ethnicity.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7571-7571.	0.8	6
13	Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide. <i>Blood Advances</i> , 2022, 6, 4098-4106.	2.5	9
14	The Cerebroventricular Environment Modifies CAR T Cells for Potent Activity against Both Central Nervous System and Systemic Lymphoma. <i>Cancer Immunology Research</i> , 2021, 9, 75-88.	1.6	24
15	A phase Ib, open label, dose escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia. <i>Investigational New Drugs</i> , 2021, 39, 1099-1105.	1.2	5
16	Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial. <i>Blood Advances</i> , 2021, 5, 1695-1705.	2.5	18
17	Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. <i>Molecular Cell</i> , 2021, 81, 2094-2111.e9.	4.5	17
18	Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7552-7552.	0.8	5

#	ARTICLE	IF	CITATIONS
19	Phase 1/2 study of cirtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology, 2021, 39, 7556-7556.	0.8	11
20	Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.. Journal of Clinical Oncology, 2021, 39, 7501-7501.	0.8	16
21	The Chronic Lymphocytic Leukemia Comorbidity Index (CLL-CI): A Three-Factor Comorbidity Model. Clinical Cancer Research, 2021, 27, 4814-4824.	3.2	23
22	Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Leukemia and Lymphoma, 2021, 62, 3278-3282.	0.6	7
23	Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma. Blood Advances, 2021, 5, 4149-4155.	2.5	42
24	CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma. Blood Advances, 2021, 5, 4059-4063.	2.5	62
25	Chronic Lymphocytic Leukemia (CLL): Biology and Therapy. Cancer Treatment and Research, 2021, 181, 133-149.	0.2	0
26	Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study. Journal of Clinical Oncology, 2021, 39, 3853-3865.	0.8	115
27	A Phase I Trial of PI3KÎ±Î³ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter's Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL). Blood, 2021, 138, 3558-3558.	0.6	3
28	Phase 1b/2 Study of Cirtuzumab and Ibrutinib in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL). Blood, 2021, 138, 3534-3534.	0.6	1
29	Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL). Blood, 2021, 138, 2840-2840.	0.6	34
30	Long-Term (â‰¥4 Year and â‰¥5 Year) Overall Survival (OS) By 12- and 24-Month Event-Free Survival (EFS): An Updated Analysis of ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Refractory Large B-Cell Lymphoma (LBCL). Blood, 2021, 138, 1764-1764.	0.6	48
31	Pharmacologic Inhibition of SUMO-Activating Enzyme Potentiates Interferon Response and T Cell-Mediated Anti-Tumor Immunity in Chronic Lymphocytic Leukemia (CLL) and Lymphoma Models. Blood, 2021, 138, 3719-3719.	0.6	0
32	MGA deletion Leads to Richter's Transformation Via NME1. Blood, 2021, 138, 252-252.	0.6	1
33	Sarcopenia Is a Clinically Relevant and Independent Predictor of Health Outcomes after Chimeric Antigen Receptor T-Cell Therapy for Lymphoma. Blood, 2021, 138, 2502-2502.	0.6	6
34	Atezolizumab Combined with Immunogenic Salvage Chemoimmunotherapy (R-GemOx+Atezo) in Patients with Transformed Diffuse Large B-Cell Lymphoma. Blood, 2021, 138, 1407-1407.	0.6	1
35	Interviews of Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Lisocabtagene Maraleucel (liso-cel) Trials on Their Treatment Experience for 3 Months after Infusion. Blood, 2021, 138, 4098-4098.	0.6	0
36	Real-World Outcomes of Axicabtagene Ciloleucel (Axi-cel) for the Treatment of Large B-Cell Lymphoma (LBCL): Impact of Age and Specific Organ Dysfunction. Blood, 2021, 138, 530-530.	0.6	9

#	ARTICLE	IF	CITATIONS
37	Nedd8-Activating Enzyme Inhibition Enhances Anti-Tumor Immunity and PD1 Blockade in <i>In Vivo</i> Lymphoma Models. <i>Blood</i> , 2021, 138, 2414-2414.	0.6	0
38	Fixed Duration Combination Therapy with Ibrutinib (ibr) and Venetoclax (ven) Leads to Deep Responses in Relapsed/Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL): Results of a Phase 2 Study. <i>Blood</i> , 2021, 138, 3754-3754.	0.6	0
39	Cancer-Associated Venous Thromboembolic Disease, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 1181-1201.	2.3	43
40	Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. <i>Leukemia and Lymphoma</i> , 2020, 61, 309-317.	0.6	22
41	A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. <i>Blood</i> , 2020, 136, 2038-2050.	0.6	281
42	Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. <i>Lancet, The</i> , 2020, 396, 839-852.	6.3	1,224
43	Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. <i>Blood Advances</i> , 2020, 4, 6009-6018.	2.5	57
44	Model of a Queuing Approach for Patient Accrual in Phase 1 Oncology Studies. <i>JAMA Network Open</i> , 2020, 3, e204787.	2.8	8
45	Toxicities Associated With Metformin/Ritonavir Combination Treatment in Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, e667-e672.	0.2	6
46	Long-Term Survival and Gradual Recovery of B Cells in Patients with Refractory Large B Cell Lymphoma Treated with Axicabtagene Ciloleucel (Axi-Cel). <i>Blood</i> , 2020, 136, 40-42.	0.6	8
47	Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study. <i>Blood</i> , 2020, 136, 16-17.	0.6	32
48	Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study. <i>Blood</i> , 2020, 136, 37-39.	0.6	37
49	Safety and Preliminary Efficacy in Patients with Relapsed/Refractory Mantle Cell Lymphoma Receiving Lisocabtagene Maraleucel in Transcend NHL 001. <i>Blood</i> , 2020, 136, 10-11.	0.6	52
50	Updated Follow-up of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated with Lisocabtagene Maraleucel in the Phase 1 Monotherapy Cohort of Transcend CLL 004, Including High-Risk and Ibrutinib-Treated Patients. <i>Blood</i> , 2020, 136, 40-41.	0.6	26
51	Transcend CLL 004: Phase 1 Cohort of Lisocabtagene Maraleucel (liso-cel) in Combination with Ibrutinib for Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2020, 136, 39-40.	0.6	40
52	Cirmtuzumab, an Anti-ROR1 Antibody, in Combination with Ibrutinib: Clinical Activity in Mantle Cell Lymphoma (MCL) or Chronic Lymphocytic Leukemia (CLL) from a Phase 1/2 Study. <i>Blood</i> , 2020, 136, 45-46.	0.6	5
53	ASPEN: Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8007-8007.	0.8	13
54	Updated results of the ASPEN trial from a cohort of patients with MYD88 wild-type (<sup>WT</sup>) Waldenström macroglobulinemia (WM).. <i>Journal of Clinical Oncology</i> , 2020, 38, e20056-e20056.	0.8	4

#	ARTICLE	IF	CITATIONS
55	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 185-217.	2.3	40
56	Characterization of cytokine release syndrome (CRS) and neurological events (NEs) in the phase I TRANSCEND NHL 001 trial of lisocabtagene maraleucel (liso-cel) for patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).. Journal of Clinical Oncology, 2020, 38, e20046-e20046.	0.8	0
57	Incidence and Causes of Prolonged Hematologic Toxicity after Chimeric Antigen Receptor T Cell Therapy: A City of Hope (COH) Experience. Blood, 2020, 136, 40-41.	0.6	2
58	Integrative Transcriptome and Quantitative Proteome Analyses Identify METTL3 As a Key Regulator for Aberrant RNA Processing in Chronic Lymphocytic Leukemia. Blood, 2020, 136, 12-12.	0.6	0
59	Qualitative Analysis of the Treatment Experience and Well-Being of Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Enrolled in 2 Trials of Lisocabtagene Maraleucel (liso-cel) during the Initial Stages of Therapy. Blood, 2020, 136, 22-23.	0.6	0
60	Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood, 2019, 134, 1811-1820.	0.6	75
61	Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematology, 2019, 6, e100-e109.	2.2	65
62	NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 12-20.	2.3	52
63	A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors. Investigational New Drugs, 2019, 37, 738-747.	1.2	12
64	Understanding Caregiver Quality of Life in Caregivers of Hospitalized Older Adults With Cancer. Journal of the American Geriatrics Society, 2019, 67, 978-986.	1.3	36
65	Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1â€”2 trial. Lancet Oncology, The, 2019, 20, 31-42.	5.1	1,467
66	Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Results from the MRD Cohort of the Phase 2 CAPTIVATE Study. Blood, 2019, 134, 35-35.	0.6	40
67	CD19-Targeting CAR-T Cell Therapy in CNS Lymphoma. Blood, 2019, 134, 4075-4075.	0.6	10
68	Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US). Blood, 2019, 134, 764-764.	0.6	77
69	A Comparison of Two-Year Outcomes in ZUMA-1 (Axicabtagene Ciloleucel) and SCHOLAR-1 in Patients with Refractory Large B Cell Lymphoma. Blood, 2019, 134, 4095-4095.	0.6	8
70	Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas. Blood, 2019, 134, 241-241.	0.6	89
71	Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisocabtagene Maraleucel (liso-cel), a CD19-Directed CAR T Cell Product: Updated Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib. Blood, 2019, 134, 503-503.	0.6	24
72	Burden of cytokine release syndrome (CRS) and neurologic events (NE) in patients (Pts) with relapsed/refractory non-Hodgkin lymphoma (NHL) receiving lisocabtagene maraleucel (Liso-cel); Tj ETQq0 0 0 rgBT Overlock 10 Tf 50 57		

#	ARTICLE	IF	CITATIONS
73	TRANSCEND CLL 004: Minimal residual disease (MRD) negative responses after lisocabtagene maraleucl (Liso-Cel; JCAR017), a CD19-directed CAR T cell product, in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).. Journal of Clinical Oncology, 2019, 37, 7501-7501.	0.8	13
74	Lisocabtagene maraleucl (liso-cel) treatment of patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL) and secondary CNS lymphoma: Initial results from TRANSCEND NHL 001.. Journal of Clinical Oncology, 2019, 37, 7515-7515.	0.8	11
75	Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for CLL and MCL. Blood, 2019, 134, 1755-1755.	0.6	1
76	Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. Biology of Blood and Marrow Transplantation, 2018, 24, 514-520.	2.0	31
77	NCCN Guidelines Insights: Cancer-Associated Venous Thromboembolic Disease, Version 2.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1289-1303.	2.3	168
78	Targeted Therapies in CLL: Monotherapy Versus Combination Approaches. Current Hematologic Malignancy Reports, 2018, 13, 525-533.	1.2	9
79	Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation. Journal of Hematology and Oncology, 2018, 11, 87.	6.9	12
80	Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia. Leukemia, 2018, 32, 1768-1777.	3.3	184
81	Rapid MRD-Negative Responses in Patients with Relapsed/Refractory CLL Treated with Liso-Cel, a CD19-Directed CAR T-Cell Product: Preliminary Results from Transcend CLL 004, a Phase 1/2 Study Including Patients with High-Risk Disease Previously Treated with Ibrutinib. Blood, 2018, 132, 300-300.	0.6	17
82	2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucl (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma. Blood, 2018, 132, 2967-2967.	0.6	13
83	Estimation of the Resource Utilization and Costs of Cytokine Release Syndrome Observed in the Transcend-NHL Clinical Trial: A Micro-Costing Study. Blood, 2018, 132, 319-319.	0.6	5
84	Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia. Blood, 2018, 132, 2888-2888.	0.6	22
85	Combination of Umbralisib, Ublituximab, and Bendamustine Is Safe and Highly Active in Patients with Advanced Diffuse Large B-Cell Lymphoma and Follicular Lymphoma. Blood, 2018, 132, 4197-4197.	0.6	1
86	The Cerebroventricular Environment Reprograms Locally Infused CAR T Cells for Superior Activity Against Both CNS and Systemic B Cell Lymphoma. Blood, 2018, 132, 965-965.	0.6	2
87	Outcomes by prior lines of therapy (LoT) in ZUMA-1, the pivotal phase 2 study of axicabtagene ciloleucl (Axi-Cel) in patients (Pts) with refractory large B cell lymphoma.. Journal of Clinical Oncology, 2018, 36, 3039-3039.	0.8	12
88	ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma.. Journal of Clinical Oncology, 2018, 36, TPS3102-TPS3102.	0.8	3
89	Factors That Influence Treatment Decision-Making: Perspectives of 1147 Chronic Lymphocytic Leukemia (CLL) Patients in the United States. Blood, 2018, 132, 4414-4414.	0.6	1
90	Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma. Molecular Therapy, 2017, 25, 285-295.	3.7	498



#	ARTICLE	IF	CITATIONS
91	Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1861-1869.	2.0	19
92	Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2017, 377, 2531-2544.	13.9	3,865
93	Hairy Cell Leukemia, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1414-1427.	2.3	24
94	Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2017, 35, 24-31.	0.8	152
95	Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry. <i>Leukemia and Lymphoma</i> , 2017, 58, 1607-1616.	0.6	46
96	Small B-cell lymphocytic lymphoma and chronic lymphocytic leukemia. , 2017, , 47-73.		0
97	Lymphoplasmacytic lymphoma in the era of next generation sequencing. , 2017, , 97-109.		0
98	Phase 1 studies of central memoryâ€‘derived CD19 CAR Tâ€‘cell therapy following autologous HSCT in patients with B-cell NHL. <i>Blood</i> , 2016, 127, 2980-2990.	0.6	264
99	Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. <i>Lancet Oncology</i> , The, 2016, 17, 1409-1418.	5.1	290
100	Burkitt leukemia limited to the bone marrow has a better prognosis than Burkitt lymphoma with bone marrow involvement in adults. <i>Leukemia and Lymphoma</i> , 2016, 57, 866-871.	0.6	5
101	Transcend NHL 001: Immunotherapy with the CD19-Directed CAR T-Cell Product JCAR017 Results in High Complete Response Rates in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2016, 128, 4192-4192.	0.6	25
102	Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 830-830.	0.6	3
103	A Phase 2 Multicenter Trial of KTE-C19 (anti-CD19 CAR T Cells) in Patients With Chemorefractory Primary Mediastinal B-Cell Lymphoma (PMBCL) and Transformed Follicular Lymphoma (TFL): Interim Results From ZUMA-1. <i>Blood</i> , 2016, 128, 998-998.	0.6	26
104	Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1. <i>Blood</i> , 2016, 128, LBA-6-LBA-6.	0.6	30
105	Long-term follow-up of the PI3KÎ´ inhibitor TGR-1202 to demonstrate a differentiated safety profile and high response rates in CLL and NHL: Integrated-analysis of TGR-1202 monotherapy and combined with ublituximab.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7512-7512.	0.8	12
106	Ongoing complete remissions (CR) in the phase 1 of ZUMA-1: a phase 1-2 multicenter study evaluating the safety and efficacy of KTE-C19 (anti-CD19 CAR T cells) in subjects with refractory aggressive B-cell Non-Hodgkin Lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7559-7559.	0.8	2
107	Cancer-Associated Venous Thromboembolic Disease, Version 1.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1079-1095.	2.3	100
108	Impact of Pretransplantation 18F-fluorodeoxy Glucoseâ€‘Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1605-1611.	2.0	39

#	ARTICLE	IF	CITATIONS
109	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 2425-2437.	13.9	1,261
110	Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2136-2140.	2.0	131
111	A phase II study of vorinostat and rituximab for treatment of newly diagnosed and relapsed/refractory indolent non-Hodgkin lymphoma. <i>Haematologica</i> , 2015, 100, 357-362.	1.7	66
112	Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results. <i>Blood</i> , 2015, 126, 1538-1538.	0.6	6
113	Phase 1 Clinical Results of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2015, 126, 3991-3991.	0.6	9
114	Results from the International, Randomized Phase 3 Study of Ibrutinib Versus Chlorambucil in Patients 65 Years and Older with Treatment-Naïve CLL/SLL (RESONATE-2TM). <i>Blood</i> , 2015, 126, 495-495.	0.6	2
115	Post Transplant Outcome of a Multicenter Phase II Study of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT. <i>Blood</i> , 2015, 126, 519-519.	0.6	9
116	Phase I Studies of Cellular Immunotherapy Using Central Memory Derived-CD19-Specific T Cells Following Autologous Stem Cell Transplantation for Patients with High-Risk Intermediate Grade B-Lineage Non-Hodgkin Lymphoma. <i>Blood</i> , 2015, 126, 930-930.	0.6	2
117	Results from a Phase 1 Study and Expanded Cohort of an Interrupted Dosing Schedule of the Aurora Kinase a Inhibitor MLN8237 Combined with Vorinostat in Lymphoid Malignancies. <i>Blood</i> , 2015, 126, 2731-2731.	0.6	0
118	Interim Analysis of a Phase 2 Study of Bortezomib Plus Rituximab Maintenance Therapy in Patients with Mantle Cell Lymphoma Status Post Autologous Stem Cell Transplantation. <i>Blood</i> , 2015, 126, 1961-1961.	0.6	0
119	Phase 1 Biomarker Analysis of the ZUMA-1 (KTE-C19-101) Study: A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of Anti-CD19 CAR T Cells (KTE-C19) in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2015, 126, 2730-2730.	0.6	2
120	Role of brentuximab vedotin in the treatment of relapsed or refractory Hodgkin lymphoma. <i>Pharmacogenomics and Personalized Medicine</i> , 2014, 7, 79.	0.4	12
121	Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1864-1868.	2.0	56
122	Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin. <i>Blood</i> , 2014, 123, 3095-3100.	0.6	280
123	Efficacy and Safety of Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia with 17p Deletion: Results from the Phase II RESONATE-17 Trial. <i>Blood</i> , 2014, 124, 327-327.	0.6	33
124	Phase 1 Study of MLN8237, an Aurora KinaseA (AURKA) Inhibitor, Combined with Vorinostat, a Histone Deacetylase (HDAC) Inhibitor, in Lymphoid Malignancies. <i>Blood</i> , 2014, 124, 4483-4483.	0.6	1
125	Results of a Phase II Trial of Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL Prior to AHCT. <i>Blood</i> , 2014, 124, 501-501.	0.6	9
126	Brentuximab Vedotin Monotherapy in DLBCL Patients with Undetectable CD30: Preliminary Results from a Phase 2 Study. <i>Blood</i> , 2014, 124, 629-629.	0.6	5



#	ARTICLE	IF	CITATIONS
127	Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3k $\gamma$ Inhibitor, Demonstrates Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma. <i>Blood</i> , 2014, 124, 801-801.	0.6	4
128	Venous Thromboembolic Disease. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1402-1429.	2.3	80
129	Brentuximab Vedotin Improves HCT-CI, CR Status, and Peri-Transplant Toxicity In Patients With Relapsed/Refractory Hodgkin Lymphoma Heading To RIC Allo-HCT. <i>Blood</i> , 2013, 122, 3374-3374.	0.6	3
130	Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma. <i>Blood</i> , 2013, 122, 4398-4398.	0.6	1
131	A Phase 2 Study of Brentuximab Vedotin in Patients with Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas: Interim Results.. <i>Blood</i> , 2012, 120, 2746-2746.	0.6	9
132	Brentuximab Vedotin As First Line Salvage Therapy in Relapsed/Refractory HL. <i>Blood</i> , 2012, 120, 3699-3699.	0.6	16
133	A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. <i>Blood</i> , 2012, 120, 3698-3698.	0.6	0
134	Does antithymocyte globulin have a place in reduced-intensity conditioning for allogeneic hematopoietic stem cell transplantation?. <i>Hematology American Society of Hematology Education Program</i> , 2012, 2012, 246-50.	0.9	8
135	Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. <i>Blood</i> , 2010, 115, 2901-2909.	0.6	46
136	A Case of HIV-Negative Primary Effusion Lymphoma Treated with Bortezomib, Pegylated Liposomal Doxorubicin, and Rituximab. <i>Clinical Lymphoma and Myeloma</i> , 2008, 8, 300-304.	1.4	41